Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination

Vaccine

Volumn 28, Issue 7, 2010, Pages 1778-1785

  van Maurik, André ^a   Sabarth, Nicolas ^a   Dacho, Helga Savidis ^a   Brühl, Peter ^a   Schwendinger, Michael ^a   Crowe, Brian A ^a   Noel Barrett, P ^a   Kistner, Otfried ^a   Keith Howard, M ^a  

^a BAXTER BIOSCIENCE   (Austria)

Author keywords

H5N1 protection; Heterosubtypic immunity; Seasonal influenza vaccine

Indexed keywords

INFLUENZA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AVIAN INFLUENZA; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMORAL IMMUNITY; IMMUNIZATION; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS STRAIN;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; CROSS REACTIONS; FEMALE; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION, PASSIVE; IMMUNIZATION, SECONDARY; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 75449107948     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.12.008     Document Type: Article

References (40)

1. Schulman J.L., and Kilbourne E.D. Induction of partial specific heterotypic immunity in mice by a single infection with influenza A virus. J Bacteriol 89 (1965) 170-174
2. Couch R.B. Seasonal inactivated influenza virus vaccines. Vaccine 26 Suppl. 4 (2008) D5-D9
3. Wood J.M. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 20 Suppl. 5 (2002) B40-B44
4. Bresson J.L., Perronne C., Launay O., Gerdil C., Saville M., Wood J., et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 367 9523 (2006) 1657-1664
5. Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 370 9587 (2007) 580-589
6. World Health Organization. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. http://www.who.int/csr/disease/avian_influenza/country/cases_table_2009_ 05_15/en/index.html, 2009.
7. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 37 4 (1999) 937-943
8. Lee L.Y., Ha do L.A., Simmons C., de Jong M.D., Chau N.V., Schumacher R., et al. Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118 10 (2008) 3478-3490
9. Jameson J., Cruz J., Terajima M., and Ennis F.A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 162 12 (1999) 7578-7583
10. Kreijtz J.H., de M.G., van Baalen C.A., Fouchier R.A., Osterhaus A.D., and Rimmelzwaan G.F. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J Virol 82 11 (2008) 5161-5166
11. Roti M., Yang J., Berger D., Huston L., James E.A., and Kwok W.W. Healthy human subjects have CD4+ T cells directed against H5N1 influenza virus. J Immunol 180 3 (2008) 1758-1768
12. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., and Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4 2 (2007) e59
13. Gioia C., Castilletti C., Tempestilli M., Piacentini P., Bordi L., Chiappini R., et al. Cross-subtype immunity against avian influenza in persons recently vaccinated for influenza. Emerg Infect Dis 14 1 (2008) 121-128
14. Lynch G.W., Selleck P.W., Axell A.-M., Downton T., Kapitza N.M., Boehm I., et al. Cross-reactive anti-avian H5N1 influenza neutralizing antibodies in a normal 'exposure-naive' Australian blood donor population. Open Immunol J 1 (2008) 13-19
15. Stelzer-Braid S., Wong B., Robertson P., Lynch G.W., Laurie K., Shaw R., et al. A commercial ELISA detects high levels of human H5 antibody but cross-reacts with influenza A antibodies. J Clin Virol 43 2 (2008) 241-243
16. Throsby M., van den Brink E., Jongeneelen M., Poon L.L., Alard P., Cornelissen L., et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3 12 (2008) e3942
17. Tumpey T.M., Renshaw M., Clements J.D., and Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 75 11 (2001) 5141-5150
18. Sambhara S., Kurichh A., Miranda R., Tumpey T., Rowe T., Renshaw M., et al. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell Immunol 211 2 (2001) 143-153
19. Takada A., Matsushita S., Ninomiya A., Kawaoka Y., and Kida H. Intranasal immunization with formalin-inactivated virus vaccine induces a broad spectrum of heterosubtypic immunity against influenza A virus infection in mice. Vaccine 21 23 (2003) 3212-3218
20. Ichinohe T., Tamura S., Kawaguchi A., Ninomiya A., Imai M., Itamura S., et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J Infect Dis 196 9 (2007) 1313-1320
21. Kistner O., Howard M.K., Spruth M., Wodal W., Brühl P., Gerencer M., et al. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25 32 (2007) 6028-6036
22. Kistner O., Barrett P.N., Mundt W., Reiter M., Schober-Bendixen S., and Dorner F. Development of a mammalian cell (Vero) derived candidate influenza virus vaccine. Vaccine 16 9-10 (1998) 960-968
23. Wood J.M., Schild G.C., Newman R.W., and Seagroatt V. An improved single-radial-immunodiffusion technique for the assay of influenza haemagglutinin antigen: application for potency determinations of inactivated whole virus and subunit vaccines. J Biol Stand 5 3 (1977) 237-247
24. Davison A.C., and Hinkley D. Bootstrap methods and their applications (1997) Cambridge
25. Holm S. A simple sequentially rejective multiple test procedure. Scand J Stat 6 (1979) 65-70
26. Reed L.J., and Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 27 (1938) 493-497
27. Aymard-Henry M., Coleman M.T., Dowdle W.R., Laver W.G., Schild G.C., and Webster R.G. Influenza virus neuraminidase and neuraminidase-inhibition test procedures. Bull World Health Organ 48 2 (1973) 199-202
28. Lu X., Tumpey T.M., Morken T., Zaki S.R., Cox N.J., and Katz J.M. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 73 7 (1999) 5903-5911
29. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., and Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354 13 (2006) 1343-1351
30. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 368 9540 (2006) 991-997
31. Ehrlich H.J., Muller M., Oh H.M., Tambyah P.A., Joukhadar C., Montomoli E., et al. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med 358 24 (2008) 2573-2584
32. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 197 5 (2008) 667-675
33. Nolan T.M., Richmond P.C., Skeljo M.V., Pearce G., Hartel G., Formica N.T., et al. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults. Vaccine 26 33 (2008) 4160-4167
34. Tang J.W., Ngai K.L., and Chan P.K. Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans. J Med Virol 80 11 (2008) 1992-1996
35. Morris A.G., Lin Y.L., and Askonas B.A. Immune interferon release when a cloned cytotoxic T-cell line meets its correct influenza-infected target cell. Nature 295 5845 (1982) 150-152
36. Oxenius A., Zinkernagel R.M., and Hengartner H. CD4+ T-cell induction and effector functions: a comparison of immunity against soluble antigens and viral infections. Adv Immunol 70 (1998) 313-367
37. Webster R.G., and Askonas B.A. Cross-protection and cross-reactive cytotoxic T cells induced by influenza virus vaccines in mice. Eur J Immunol 10 5 (1980) 396-401
38. Suzuki Y., and Nei M. Origin and evolution of influenza virus hemagglutinin genes. Mol Biol Evol 19 4 (2002) 501-509
39. Kashyap A.K., Steel J., Oner A.F., Dillon M.A., Swale R.E., Wall K.M., et al. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci USA 105 16 (2008) 5986-5991
40. Qin C.F., and Qin E.D. Seasonal influenza vaccination may mitigate the potential impact of an H5N1 pandemic. Chin Med J (Engl) 121 15 (2008) 1481-1483